Abstract
Get full access to this article
View all access options for this article.
References
1.
Guttman
M
Kish
SJ
Fufrkawa
Y
. Current concepts in the diagnosis and management of Parkinson’s disease . CMAJ 2003 ;168 :293 -301 .
2.
Lang
AE
Lozano
AM
. Parkinson’s disease: first of two parts . N Engl J Med 1998 ;339 :1044 -53 .
3.
Lang
AE
Lozano
AM
. Parkinson’s disease: second of two parts . N Engl J Med 1998 ;339 :1130 -43 .
4.Parkinson Society Canada . Parkinson’s disease: social and economic impact . Available: www.parkinson.ca/site/c.kgLNIWODKpF/b.5184077/k.CDD1/What_is_Parkinsons.htm (accessed Jan. 26, 2014 ).
5.
Guttman
M
Slaughter
PM
Theriault
ME
. Burden of parkinsonism: a population-based study . Mov Disord 2003 ;18 :313 -9 .
6.
Perepelkin
J
. Public opinion of pharmacists and pharmacist prescribing . Can Pharm J (Ott) 2011 ;144 :86 -93 .
7.
Grimes
D
Gordon
J
Snelgrove
B
. Canadian guidelines on Parkinson’s disease . Can J Neurol Sci 2012 ;39 Suppl 4 :S1 -30 . Available : www.parkinsonclinicalguidelines.ca/sites/default/files/PD_Guidelines_2012.pdf (accessed Feb. 6, 2014 ).
8.
Olanow
CW
Stern
MB
Sethis
K
. The scientific and clinical basis for the treatment of Parkinson disease (2009) . Neurology 2009 ;72 (Suppl 4 ):S1 -136 .
9.Lexi-Comp Inc. Lexi-Comp online . Hudson (OH) : Lexi-Comp Inc. ; 2014 . Available: http://online.lexi.com/lco/action/home/ (accessed Jan. 29, 2014 ).